In a statement released on June 20, 2023, pharmaceutical company Novo Nordisk has announced that it has initiated legal proceedings against certain medical spas, weight loss or wellness clinics, and compounding pharmacies in the U.S. The company is attempting to stop entities from advertising and selling compounded products claiming to contain semaglutide, the active ingredient in Novo Nordisk’s medications Ozempic, Wegovy, and Rybelsus. Ozempic and Wegovy have been on the Food and Drug Administration’s (FDA’s) Drug Shortages list since last year. Despite Novo Nordisk’s claim that these practices have led to consumer confusion, deception, and potential safety concerns, making compounded versions of commercially available drugs is permissible under special circumstances, like a shortage, according to the FDA. “When a drug is in shortage, compounders may be able to prepare a compounded version of that drug if they meet certain requirements of the Federal Food, Drug, and Cosmetic (FD&C) Act,” the FDA said.
If you are currently facing legal proceedings initiated by Novo Nordisk, we strongly advise you to promptly contact the attorneys at Frier Levitt. Our team possesses extensive expertise in representing various compounding entities throughout the country, making us well-equipped to offer a comprehensive range of services. By engaging with Frier Levitt, you can expect not only a high level of certainty of exceptional client satisfaction but also a steadfast commitment to protecting your rights and advocating for your best interests. Our attorneys are dedicated to providing personalized attention and strategic guidance throughout the legal process.